| Cash flow (USD) | FY 2025 ended Dec 31, 2025 | FY 2024 ended Dec 31, 2024 | FY 2023 ended Dec 31, 2023 | FY 2022 ended Dec 31, 2022 | FY 2021 ended Dec 31, 2021 | FY 2020 ended Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Net income | 2.90B | 1.85B | 1.57B | 642.00M | 985.00M | -115.00M |
| Depreciation and amortization | 1.37B | 1.27B | 1.20B | 1.14B | 1.09B | 1.12B |
| Stock-based compensation | 299.00M | 266.00M | 233.00M | 220.00M | 194.00M | 170.00M |
| Cash from operations | 4.53B | 3.44B | 2.50B | 1.53B | 1.87B | 1.51B |
| Capital expenditure | -876.00M | -790.00M | -711.00M | -588.00M | -554.00M | -376.00M |
| Free cash flow | 3.66B | 2.65B | 1.79B | 938.00M | 1.32B | 1.13B |
| Acquisitions | -1.59B | -4.64B | -1.81B | -1.54B | -2.26B | -3.00M |
| Cash from investing | -2.64B | -5.69B | -2.57B | -2.01B | -1.60B | -411.00M |
| Dividends paid | 0 | -28.00M | -55.00M | -55.00M | -28.00M | |
| Share buybacks | 0 | 0 | -535.00M | |||
| Cash from financing | -395.00M | 1.81B | 5.00M | -548.00M | -95.00M | 293.00M |
| Net change in cash | 1.54B | -450.00M | -70.00M | -1.04B | 173.00M | 1.39B |
From Boston Scientific's 10-K and 10-Q filings with the SEC. Fiscal years are the company's own, so they may not match the calendar. A blank cell means the company did not report that line. New to this? Read cash flow or reading a 10-K.
Revenue, earnings, margins and balance sheet trends drawn by TradingView from its own data, so figures can differ slightly from the SEC table above.